ClinicalTrials.gg
CompletedNCT03427502Updated Sep 11, 2020

Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation

An interventional study of Bupivacaine-epinephrine and normal saline in Postoperative Agitation: Impaired Awareness, Abnormal Cognitive Function, Confusion, and Verbal and Physical Agitation During Recovery From General Anesthesia, Deviated Nasal Septum and Chronic Rhinosinusitis (Diagnosis), sponsored by Lumbini Medical College. Completed at 1 site in Nepal. Per ClinicalTrials.gov, last updated 2020-09-11.

Sponsored by Lumbini Medical College · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Study summary

Postoperative agitation is an important complication of general anesthesia, moreover, it has been found with high incidence in ear, nose, throat (ENT) surgeries. We aim to study whether anterior ethmoidal nerve block will be successful in reducing postoperative agitation in those patients. Study population will be randomized into two groups, treatment and control group. Anterior ethmoidal nerve block will be done in treatment group and postoperative agitation compared between these two groups. Agitation score will be scored with Riker Sedation-Agitation Scale (SAS).

Ho: Occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is equal in those with ethmoidal nerve block as compared to those without the block.

Ha: Occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is not equal in those with ethmoidal nerve block as compared to those without the block.

02

Conditions studied

  • Postoperative Agitation: Impaired Awareness, Abnormal Cognitive Function, Confusion, and Verbal and Physical Agitation During Recovery From General Anesthesia
  • Deviated Nasal Septum
  • Chronic Rhinosinusitis (Diagnosis)
  • Nasal Polyps

Keywords

  • general anesthesia
  • nasal surgery
  • anterior ehtmoidal nerve block
  • bupivacaine
  • postoperative confusion
03

In context

Confusion

88 studies on the registry are indexed under Confusion; 19 are open to participants now.

This study's enrollment of 100 is below the median of 115 across 56 interventional studies indexed under Confusion.

Browse Confusion studies →

Lead sponsor

Lumbini Medical College is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing nasal surgery
  • Under General Anesthesia
  • With nasal packs

Exclusion criteria

Exclusion Criteria:

  • Do not consent to the study.
  • History of allergy to lignocaine or bupivacaine
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Study Group

    Experimental: Study Group At the end of surgery before nasal packing, scrub nurse will prepare 10 ml solution 0.5% bupivacaine with 1:2,00,000 adrenaline in a syringe and pass it over to the operating surgeon. The surgeon will block anterior ethmoidal nerve. Injection technique: External nasal nerve will be blocked through an inter-cartilaginous injection into the dorsum of the nose. Internal nasal nerve will be blocked in septum and lateral wall of nose. Septal block is done in upper anterior part of nasal septum. Three injections will be given on lateral nasal wall. First injection will be given just antero-superior to the attachment of middle turbinate (axilla). Second injection will be given at the anterior end of middle turbinate and third injection at the medial surface of middle turbinate. Withdrawal of injection will be done prior to deposition of solution every time to ensure that the solution is not deposited directly into a blood vessel.

    Drug: Bupivacaine-epinephrine

  • Placebo comparator
    Control Group

    At the end of surgery before nasal packing, scrub nurse will pass 10 ml of normal saline in a syringe to the surgeron. Injection technique remains the same as in Study group.

    Drug: normal saline

Interventions

  • DrugBupivacaine-epinephrine

    Drug pages: Bupivacaine · Epinephrine

    10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline

  • Drugnormal saline

    normal saline

06

What researchers measure

Primary outcomes

  1. Postoperative agitation

    It will be assessed with Riker Sedation-Agitation Scale (SAS). It is a Likert scale with scores from 1 to 7 where 1 indicates unarousable (Minimal or no response to noxious stimuli, does not communicate or follow commands) and 7 indicates Dangerous agitation (Pulling at ET tube, trying to remove catheters, climbing over bedrail, striking at staff, thrashing side-to-side). A higher value indicates worse outcome.

    Time frame: After extubation before leaving operation table, an average of 10 minutes

  2. Postoperative agitation

    It will be assessed with Riker Sedation-Agitation Scale (SAS). It is a Likert scale with scores from 1 to 7 where 1 indicates unarousable (Minimal or no response to noxious stimuli, does not communicate or follow commands) and 7 indicates Dangerous agitation (Pulling at ET tube, trying to remove catheters, climbing over bedrail, striking at staff, thrashing side-to-side). A higher value indicates worse outcome.

    Time frame: 30 minutes after first score.

  3. Postoperative agitation

    It will be assessed with Riker Sedation-Agitation Scale (SAS)

    Time frame: 9:00 AM next morning

07

Study locations

1 site
  • Lumbini Medical College
    Tansen, Palpa 32500, Nepal
08

References and documents

Individual participant data

Plan to share: Undecided — All data except patients name and address may be shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03427502
Lead sponsor
Lumbini Medical College
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
Jun 1, 2018
Primary completion
Dec 30, 2019
Completion
Feb 28, 2020
Last update
Sep 11, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Epinephrine

Start the discussion